Sofosbuvir: an antiviral drug with potential efficacy against Zika infection

International Journal of Infectious Diseases

Volumn 55, Issue , 2017, Pages 29-30

  Reznik, Sandra E ^a,b   Ashby, Charles R ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DRUG METABOLITE; GALIDESIVIR; SOFOSBUVIR;

AMINO ACID SEQUENCE; ANTIVIRAL THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; NONHUMAN; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VOLUME OF DISTRIBUTION; ZIKA FEVER; ZIKA VIRUS;

EID: 85009851591     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2016.12.011     Document Type: Short Survey

References (17)

1. 1 Weaver, S.C., Costa, F., Garcia-Blanco, M.A., Koop, A.I., Ribeiro, G.S., Saade, G., et al. Zika virus: history, emergence, biology, and prospects for control. Antiviral Res 130 (2016), 69–80.
2. 2 Musso, D., Gubler, D.J., Zika virus. Clin Microbiol Rev 29 (2016), 487–524.
3. 3 Petersen, L.R., Jamieson, D.J., Powers, A.M., Honein, M.A., Zika virus. N Engl J Med 374 (2016), 1552–1563.
4. 4 Cox, B.D., Stanton, R.A., Schinazi, R.F., Predicting Zika virus structural biology: challenges and opportunities for intervention. Antivir Chem Chemother 24 (2016), 118–126.
5. 5 Sofia, M.J., Nucleotide prodrugs for the treatment of HCV infection. Adv Pharmacol 67 (2013), 39–73.
6. 6 Zmurko, J., Marques, R.E., Schols, D., Verbeken, E., Kaptein, S.J., Neyts, J., The viral inhibitor 7-deaza-2′-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl Trop Dis, 10, 2016, e0004695.
7. 7 Eyer, L., Nencka, R., Huvarova, I., Palus, M., Joao Alves, M., Gould, E.A., et al. Nucleoside inhibitors of Zika virus. J Infect Dis 214 (2016), 707–711.
8. 8 Elfiky, A.A., Zika viral polymerase inhibition using anti-HCV drugs both in the market and under clinical trials. J Med Virol 88 (2016), 2044–2051.
9. 9 Sacramento, C.Q., de Melo, G.R., Rocha, N., Hoelz, L.V.B., Mesquita, M., de Freitas, C.S., et al. The clinically approved antiviral drug sofosbuvir impairs Brazilian Zika virus replication. BioRxiv, 2016 http//dx.doi.org/10.1101/061671.
10. 10 Julander, J.G., Siddharthan, V., Evans, J., Taylor, R., Tolbert, K., Apuli, C., et al. Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antiviral Res 137 (2017), 14–22.
11. 11 Kirby, B.J., Symonds, W.T., Kearney, B.P., Mathias, A.A., Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet 54 (2015), 677–690.
12. 12 Keating, G.M., Vaidya, A., Sofosbuvir: first global approval. Drugs 74 (2014), 273–282.
13. 13 Product information. Sovaldi (sofosbuvir). Foster City, CA: Gilead Sciences, Inc.; 2015 August.
14. 14 Bullard-Feibelman, K.M., Govero, J., Zhu, Z., Salazar, V., Veselinovic, M., Diamond, M.S., Geiss, B.J., The FDA approved drug Sofosbuvir inhibits Zika virus infection. Antiviral Res 137 (2017), 134–140.
15. 15 Retallack, H., Di Lullo, E., Arias, C., Knopp, K.A., Laurie, M.T., Sandoval-Espinosa, C., et al. Zika virus cell tropism in the developing human brain and inhibition. Proc Natl Acad Sci, 2016 Nov 29. pii: 201618029. [Epub ahead of print].
16. 16 Eyer, L., Nencka, R., Huvarova, I., Palus, M., Alves, M.J., Gould, E.A., et al. Nucleoside inhibitors of Zika virus. J Infect Dis 214 (2016), 707–711.
17. 17 Lu, G., Bluemling, G.R., Collop, P., Hager, M., Kuiper, D., Gurale, B.P., et al. Analysis of ribonucleotide 5′-triphosphate analogs as potential inhibitors of Zika virus RNA-dependent RNA polymerase using non-radioactive polymerase assays. Antimicrob Agents Chemother, 2016, 10.1128/AAC.01967-16.